Compare Ascendis Pharma A/S (ASND) vs iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares iBoxx $ Inv Grade Corporate Bond ETF — how do they compare? Ascendis Pharma A/S trades at $265.33 (market cap $17.74B), while iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $106.93. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares iBoxx $ Inv Grade Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | LQD | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $112.91 |
52-Week Low | $163.32 | $107.12 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
LQD trades at $107.46, down 0.23% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at oversold levels. Recent dividend payments of $0.38-$0.42 demonstrate income generation capability amid broader bond market uncertainty. Market focus remains on Federal Reserve policy direction and inflation trends affecting corporate bond valuations.
The outlook remains cautious as bond ETFs face headwinds from potential rate hikes. Income investors may find value in LQD's yield, but rising rates could pressure bond prices. Key risks include Fed policy uncertainty and narrowing market breadth in fixed income markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →
